P-153 Focus on RAS codon 61 mutations in metastatic colorectal cancer (mCRC): A retrospective analysis
نویسندگان
چکیده
Nowadays, RAS mutational status remains a key determinant in mCRC patients’ therapeutic algorithm. Mutations involving codon 61 are rare, accounting for 1-4%, but have been recently identified with high frequency ctDNA of pts secondary resistance to anti-EGFR mAbs, prevalence 50% the Chronos trial. Despite growing clinical relevance these mutations, evidence on clinicopathological features and prognosis harboring mutations is limited relies small retrospective studies. In 2014, cohort study 19 KRAS mutated (mt) reported molecular similar 12 13 mt mCRC. This an observational, retrospective, monocentric study, aiming investigate describe phenotype prognostic performance or NRAS Pts mCRC, treated at Fondazione Policlinico Gemelli between January 2013 December 2021 were enrolled. Additional datasets wt (non-codon mt, BRAF V600E RAS/BRAF wt) our Center during same time period used as comparators. Differences groups categorical variables compared using Chi Square test. Endpoint assessment was OS, estimated Kaplan-Meier method log-rank Statistical significance set p = .05. 50 included. The comparator dataset included 648 Interestingly, 54% developed peritoneal and/or ovary metastases their disease history. Metastatic involvement peritoneum significantly more frequent (54 vs 28.5%, p= . 000163), retained when comparing non 35.6%, p=.012495), 25%, p=.001286) 20.5%, < .00001) cohorts. At median FU 96.2 m, mOS shorter (26.9 36.0 HR 0.56, .0006) while no significant difference observed 30.2 .0993) 22.6 .9124). We showed statistically correlation metastatic ovary. first impact metastatization pattern. addition, data negative other non-codon mt. These warrant further validation wider prospective setting.
منابع مشابه
Review Of The Current Status Of Ras Mutation Testing In Patients With Metastatic Colorectal Cancer (Mcrc): Flash-Ras Study.
متن کامل
Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC)
Management of metastatic colorectal cancer requires a multimodal approach and must be performed by an experienced, multidisciplinary expert team. The optimal choice of the individual treatment modality, according to disease localization and extent, tumor biology, and patient clinical characteristics, will be one that can maintain quality of life and long-term survival, and even cure selected pa...
متن کاملMetastatic Colorectal Cancer: Focus on Panitumumab
Biologic agents designed as targeted therapy are at the forefront of research in the field of colorectal cancer. Monoclonal antibodiestargetingtheepidermalgrowthfactorreceptor(EGFR)representonesuchformoftreatment,andthenovelagentpanitumumab is the first fully-human monoclonal antibody developed in this class. This drug is generally well-tolerated, with skin toxicities simila...
متن کاملKRAS and BRAF mutations in Iranian colorectal cancer patients: A systematic review and meta-analysis
Background: Mutations in the EGFR signaling pathway play an important role in the development of colorectal cancer (CRC). Mutations in these genes, like KRAS and BRAF, affect the treatment strategies and associated with poor prognosis and relative resistance to anti-EGFR therapies. Our aim was to conduct a systematic and meta-analysis on all studies that have been conducted on the prevalence of...
متن کاملK-ras oncogene codon 12 point mutations in testicular cancer.
A significant association between N-ras oncogene activating point mutations and testicular cancer has recently been reported. We have studied DNA samples from the blood and fresh tumor tissues of 17 Norwegian testicular cancer patients (11 seminomas/6 nonseminomas). Point mutations in K-ras-2 and N-ras exons 1 and 2 were studied by denaturing gradient gel electrophoresis (DGGE) and by oligonucl...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Annals of Oncology
سال: 2023
ISSN: ['0923-7534', '1569-8041']
DOI: https://doi.org/10.1016/j.annonc.2023.04.209